Novartis announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ianalumab (VAY736), an investigational therapy for Sjögren’s disease. This milestone positions ianalumab to potentially become the first-ever targeted treatment for the chronic, debilitating autoimmune condition, which currently lacks approved disease-modifying therapies.
The designation is supported by robust clinical evidence from the Phase III NEPTUNUS-1 and NEPTUNUS-2 trials. In these pivotal studies, ianalumab met its primary endpoints, demonstrating a statistically significant reduction in disease activity and a meaningful improvement in patient-reported outcomes.
A Novel Approach: The Dual Mechanism of Action
Unlike traditional immunosuppressants that broadly dampen the immune system, ianalumab is a fully human monoclonal antibody designed with a novel dual mechanism. It targets the B-cell activating factor receptor (BAFF-R) to address the root causes of the disease:
- B-cell Depletion: It directly eliminates B-cells, the white blood cells responsible for the autoimmune attack—through enhanced antibody-dependent cellular cytotoxicity (ADCC).
- Survival Blockade: It simultaneously blocks BAFF-R signaling, which prevents the remaining B-cells from activating and surviving.
Sjögren’s disease is the second most prevalent rheumatic autoimmune condition, yet it remains significantly underdiagnosed. It is estimated that 0.25% of the population is affected, with nearly 50% of cases remaining unrecognized due to the disease’s complex and heterogeneous nature.
Key Symptoms and Risks of Sjögren’s Disease:
This Breakthrough Therapy designation recognizes the potential for ianalumab to substantially improve the standard of care for people with Sjögren’s disease, who currently don’t have effective treatment options.
Angelika Jahreis
- Systemic Dryness: Severe dry eyes and mouth, often leading to dental decay and corneal damage.
- Chronic Fatigue and Pain: Debilitating exhaustion and joint/muscle pain that impact daily quality of life.
- Organ Impact: Potential damage to the lungs, kidneys, and nervous system.
- Lymphoma Risk: Patients face a significantly higher risk of developing cancer of the lymph nodes.
Last Modified:
